Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.
Amarin announced a new marketing strategy for the company’s Vascepa drug in the United States, starting with reducing the Irish-American biopharmaceutical firm’s sales rep numbers by more than 50 percent.
Light-to-moderate alcohol consumption is linked to a reduced risk of heart attack, stroke and death among those with heart disease, according to a study published in the journal BMC Medicine on July 26.
AstraZeneca Plc said on March 14 a review of safety data of people vaccinated with the company’s Covid-19 vaccine has shown no evidence of an increased risk of blood clots.
When it comes to matters of heart health, no amount of exercise is too much, scientists said regarding research that debunks the myth that high levels of vigorous physical activity might not always be beneficial.
A new study published in Nature suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
Novartis boss Vas Narasimhan expects higher sales and profitability for 2020, lifted by the company’s broad range of medicines, and minimal disruption to the Swiss drugmaker’s supply chain from the coronavirus outbreak in China.
Amarin Corporation plc announced the launch of True To Your Heart, an educational campaign to help people learn more about cardiovascular disease and how to better protect against persistent cardiovascular risk.
First-time marathon runners can add years to their lives and reap the health rewards of lower blood pressure and healthier arteries, even if they take on the challenge in mid-to-later life, research showed.